Cart
sales@molnova.com
Cleomiscosin B
CAS No. 76985-93-8
Cleomiscosin B( —— )
Catalog No. M31296 CAS No. 76985-93-8
Cleomiscosins A, B and C exhibit liver-protective properties. Cleomiscosin B shows the potent anti-HIV-1 activity in vitro and also has protective effects on MT4 cells infected by HIV-1(IIIB).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 486 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCleomiscosin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionCleomiscosins A, B and C exhibit liver-protective properties. Cleomiscosin B shows the potent anti-HIV-1 activity in vitro and also has protective effects on MT4 cells infected by HIV-1(IIIB).
-
DescriptionCleomiscosins A, B and C exhibit liver-protective properties. Cleomiscosin B shows the potent anti-HIV-1 activity in vitro and also has protective effects on MT4 cells infected by HIV-1(IIIB).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number76985-93-8
-
Formula Weight386.36
-
Molecular FormulaC20H18O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
6-Methyl-3-pyridinec...
6-Methyl-3-pyridinecarboxaldehyde (6-Methoxynicotinaldehyde) has partial antitumor activity.
-
Promethazine Sulfoxi...
Promethazine sulfoxide is a metabolite of the histamine H1 receptor antagonist Promethazine.It is formed from promethazine by the cytochrome P450 (CYP) isoform CYP2D6.
-
Lanthanum trichlorid...
Lanthanum trichloride can be used as an analytical reagent and can be used as a raw material for extracting metal lanthanum and as a petroleum cracking catalyst.
